Bruce S Stambler, Francis Plat, Philip T Sager, Silvia Shardonofsky, Douglas Wight, Diane Potvin, A Shekhar Pandey, James E Ip, Benoit Coutu, Blandine Mondésert, Laurence D Sterns, Matthew Bennett, Jeffrey L Anderson, Roger Damle, Ronald Haberman, A John Camm
BACKGROUND: Pharmacologic termination of paroxysmal supraventricular tachycardia (PSVT) often requires medically supervised intervention. Intranasal etripamil, is an investigational fast-acting, nondihydropyridine, L-type calcium channel blocker, designed for unsupervised self-administration to terminate atrioventricular nodal-dependent PSVT. Phase 2 results showed potential safety and efficacy of etripamil in 104 patients with PSVT. METHODS: NODE-301, a phase 3, multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of etripamil nasal spray administered, unsupervised in patients with symptomatic sustained PSVT...
December 2022: Circulation. Arrhythmia and Electrophysiology